3[3]Morris RS, Wong IL, Kirkham E, et al. Inhibition of ovarian droven prorenin to angiotensin cascade in the treatment of ovarian hyperstimulation syndrome. Hum Reprod, 1998,13:2068-2071.
5[5]Dovrak HF, Nagy JA, Feng D, et al. Vascular perme ability factor/vascular endothelial growth factor andthe significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol, 1999,237:97-132.
6[6]Robertson D, Selleck K, Suikkari AM, et al. Urinary vascular endothelial growth factor concentration in women undergoing gonadotrophin treatment, Hum Reprod, 1995,10:1377-1482.
7[7]Rizk B, AbouLghar M, Smizt J, et al. The role of vas cular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulate syn drome. Hum Reprod Update, 1997,3:255-266.
8[8]Neulen J, Yan Z, Raczek S, et al. Human chorionic gonadotropin dependent expression of vascular en dothelial growth factor/vascular permeability factor in human granulosa cell: importance in ovarian hyper stimulation syndrome. J Clin Endocrinol Metab,1995,80:1967-1971.
9[9]Geva E, Amit A, Lessing JB. Follicular fluid levels of vascular endothelial growth factor. Are they predictive markers for ovarian hyperstimulation syndrome? J Re prod Med, 1999,44:91-96.
10[10]Revel A, Barak V, Lavy Y, et al. Characterization of intraperitoneal cytokines and nitrites in woman with severe ovarian hyperstimulation syndrome. Fertil Ster il, 1996,66:66-71.
